Tafasitamab-lenalidomide for relapsed/refractory DLBCL: real-world data from the GELTAMO study
The combination of tafasitamab and lenalidomide (tafa-len) is an effective treatment for patients with relapsed/refractory (R/R) DLBCL who are ineligible for intensive therapy. During ASH 2024, Prof Dr Antonio Gutierrez (University Hospital Son Espases, Palma de Mallorca, Spain) presented updated results of the GELTAMO study evaluating the real-life efficacy and safety of tafa-len in R/R DLBCL patients treated with this regimen across 39 Spanish centers. In the efficacy cohort (N=83) tafa-len proved to be associated with an overall response rate (ORR) of 61% (42% complete responses) and a median progression-free (PFS) and overall survival (OS) of 10.9 and 21.8 months, respectively. The best results with tafa-len were obtained in patients with an ECOG performance status of 0-1, in patients with relapsing rather than refractory disease, non-double hit patients and patients who received tafa-len in 2nd or 3rd line. Furthermore, the analysis revealed that the relative dose intensity of tafa-len was associated with a better PFS and a longer duration of response.
Made possible with the financial support of our partners.
All videos are developed independently and are non-promotional.
